Background. -Echocardiography is recommended for all patients with a clinical diagnosis of heart failure (HF). Management of HF in daily practice differs from guidelines. Aim. -To evaluate the prognostic impact of echocardiography in patients hospitalized for a first episode of HF. Methods. -Consecutive patients (n = 799) hospitalized for a first episode of HF were prospectively enrolled during 2000. Propensity scores and multivariable analyses were used to reduce the imbalance in baseline covariates between the Echo and No-Echo groups.
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Background
The incidence and prevalence of heart failure (HF) have now reached epidemic proportions. As patients with this condition face a high risk of hospitalization and mortality, HF has become an increasingly important economic issue. European and American guidelines support the major role of echocardiography in the initial evaluation of patients with HF [1, 2] . Echocardiography is a cost-effective modality, suitable for evaluating morphological and functional cardiac abnormalities in HF. It identifies the underlying causes and helps to improve the management of patients with HF primarily by assessing response to therapy. Significant differences exist between clinical guidelines in HF and routine clinical practice. In the EuroHeart Failure Survey that included patients with suspected or confirmed HF, echocardiography was performed in 66% of cases [3] . To our knowledge, only one study, which was retrospective in design, has reported the impact of echocardiography on mortality in patients hospitalized for HF [4] . The aims of the current prospective study, which included consecutive patients admitted to hospital for a first episode of HF, were:
• to analyse the clinical features and treatment of patients in whom echocardiography was not performed during the initial hospitalization, and; • to determine whether the use of echocardiography is associated with better clinical outcomes.
Methods
Study population and data collection
The Somme is a French department with a population of 555,551 inhabitants according to the 1999 census. It has a total of 11 healthcare institutions managing patients with HF: one university hospital, seven general hospitals, two private clinics, and one medium-to-long-stay unit. General practitioners, cardiologists and internal physicians in all of these centres agreed to participate in this study. Consecutive patients aged greater or equal to 20 years who were hospitalized in 2000 for a first episode of HF in these institutions were enrolled prospectively. Patients living outside the Somme department, patients hospitalized for subsequent episodes of HF, and patients with severe valvular heart disease requiring surgery were excluded. The diagnosis of HF was made by the attending physician based on history, symptoms, physical signs and admission chest X-ray. During the index hospitalization, two cardiologists specifically recruited for this purpose reviewed all medical records to validate the diagnosis of HF according to the Framingham criteria amended by the European Society of Cardiology [5] . The diagnosis was not validated in 12 of the 811 patients enrolled. Therefore, 799 patients (410 men and 389 women) were finally included. Sixty-four (8%) patients died during the index hospitalization and 735 (92%) were discharged alive.
Clinical data, including medical history, cardiovascular risk factors and results of complementary investigations (laboratory tests, electrocardiogram, admission chest X-ray, echocardiography and coronary angiography) were recorded on individual case report forms.
Echocardiography was performed during the index hospitalization in 648 patients, representing 81% of the study population. Echocardiograms were performed according to the guidelines of the American Society of Echocardiography [6] , were recorded on paper, stored in the patient's file, and analysed off-line. Results of echocardiograms performed before the index hospitalization for HF were not available. The cohort was divided in two groups: patients who underwent an echocardiography during the index hospitalization (Echo group) and patients in whom this investigation was not performed (No-Echo group).
Medical treatment records were completed at admission and at discharge. Prescription of the main therapeutic classes of drugs for HF (angiotensin-converting enzyme [ACE]-inhibitors, beta-blockers, aldosterone antagonists, diuretics, digoxin, oral anticoagulants, platelet aggregation inhibitors, amiodarone, angiotensin receptor blockers and nitrates) was recorded.
Prognosis
One-year and three-year overall mortality, and cardiovascular mortality after admission, were determined. Sudden death was classified as cardiovascular death. Vital status was obtained either by consulting the general practitioner or referring cardiologist or by referring to the civil registry. Cause of death was ascertained from hospital records, death certificates and autopsy records or by contacting the patients' physician or referring cardiologist. No patients were lost to follow-up.
Statistical analysis
Continuous variables are expressed as mean ± standard deviation and were compared using Student's t-tests. Categorical variables are summarized by frequency percents and were analysed using 2 tests. Univariate and multivariable analyses of overall and cardiovascular mortality were made using Cox proportional hazards models. The analysis of cardiovascular mortality of the two groups (Echo and No-Echo) was performed in a Cox multivariable model while patients who died of noncardiovascular causes were censored (as non-events) at the time of death. For multivariable analyses of mortality, we used a predefined Cox multivariable model including covariates of potential prognostic importance: age, sex, history of hypertension, ischaemic aetiology, diabetes mellitus, chronic obstructive pulmonary disease (COPD), cancer, stroke, estimated glomerular filtration rate, natremia, cardiomegaly, and hospitalization in cardiology departments. Separate multivariable analyses were performed in patients discharged alive (n = 735), with adjustment for the abovementioned covariates and medical therapy at discharge (ACE-inhibitors, beta-blockers, aldosterone antagonists, oral anticoagulants, amiodarone, and nitrates). The assumption of proportional hazards was checked using log-minus-log survival plots and by examining time-dependent covariates. For continuous variables, the assumption of linearity was assessed by plotting residuals against independent variables. Age, estimated glomerular filtration rate and natremia were entered in the models as continuous variables. Adjusted overall mortality curves for the two groups (Echo and NoEcho) were constructed after adjustment for the set of covariates in the multivariable model.
We further used Cox multivariable models to calculate hazard ratios (HR) with 95% confidence intervals (CI) for analysis of the effect of echocardiography performance on overall mortality by subgroups including age (cut-off 80 years), sex, history of hypertension, coronary artery disease, diabetes mellitus, COPD, renal insufficiency (cut-off for estimated glomerular filtration rate 60 mL/min per 1.73 m 2 ) and cardiomegaly. First-order interaction terms between performance of echocardiography and the above covariates were also tested.
Data on survival of the two groups (Echo and No-Echo) were compared with the expected survival of persons of the same age and sex in the Somme department. Control data were obtained from French life tables of the Somme department for 1999 provided by the French Institute of Statistics (INSEE) and represent the survival of the Somme general population. The relative survival was computed as the ratio of the observed to expected survival (observed number of deaths/expected number of deaths in the general population).
Since at admission patients were not randomly assigned to have an echocardiography, selection biases were adjusted for by developing a propensity score of echocardiography performance. We estimated the propensity scores (likelihood of performing an echocardiography) at admission for each of the 799 patients by maximum likelihood regression analysis, using a multivariable logistic model, as described previously [7, 8] . Baseline characteristics associated with the performance of echocardiography on univariate analysis (p ≤ 0.2) were included in the multivariable model in a forward stepwise regression analysis. The goodness-of-fit, assessed by the Hosmer-Lemeshow test (p = 0.58), and discriminatory power of the model (area under the receiver operating characteristic curve; C = 0.80) were good. Propensity scores were then used to match each patient in the No-Echo group to a unique patient from the Echo group with a propensity score within 2%. First, we matched each patient in the No-Echo group with another patient in the Echo group that had the same five-digit propensity score and removed the matched patients from the database. The In the group that resulted after matching, the mean propensity score was 0.70764 in patients in whom echocardiography was not performed, comparable to that of the Echo group (0.71716; p = 0.985). The baseline characteristics of the groups that resulted after matching were compared using Student's t-tests and 2 tests, as appropriate. After the matching procedure, no differences in baseline variables were observed between the two groups ( Table 1) . Adjustment for covariates of prognostic importance and confounding (propensity score entered as a linear term) were performed in additional Cox proportional analyses in the postmatch cohort.
For all tests, p ≤ 0.05 was considered statistically significant. All p values resulted from two-sided tests. Statistical analysis was performed with SPSS 13.0 (SPSS Inc., Chicago, IL, USA).
The study complies with the Declaration of Helsinki and was approved by local institutional review boards. Informed consent was obtained from all patients. The database was approved by the French computers and privacy commission.
Results
Baseline characteristics and treatment
Seven hundred and ninety-nine consecutive patients were included. The mean age of the study population was 75 ± 12 years (sex ratio: 1.05). Echocardiography was not performed during the index hospitalization in 151 patients (19%: No-Echo group). Baseline characteristics of patients according to the performance of an echocardiogram are shown in Table 1 . Patients in the No-Echo group were older and comprised a larger proportion of women. The clinical severity of HF on admission (New York Heart Association [NYHA] functional class) and the frequency of hypertension, prior myocardial infarction and comorbidities such as diabetes, stroke, COPD and cancer were not significantly different between patients in the Echo and No-Echo groups. Patients in whom echocardiography was performed had a significantly lower rate of renal insufficiency, and more often presented with cardiomegaly on the chest X-ray. Echocardiography was performed in a significantly higher proportion of patients admitted to cardiology departments versus those admitted to geriatric departments. Hospitalization in departments other than cardiology (HR 7.1, 95% CI 4.5-11.2, p < 0.001), advanced (≥ 80 years) age (HR 2.4, 95% CI 1.5-3.7, p < 0.001), and absence of cardiomegaly on chest X-ray (HR 1.5, 95% CI 0.97-2.4, p = 0.06) were independent parameters associated with the decision not to perform echocardiography.
Valvular heart disease and idiopathic dilated cardiomyopathy were significantly more frequent in the Echo group (11.0% vs. 0.7%, p < 0.001 and 12.5% vs. 0.7%, p < 0.001, respectively) whereas the frequencies of ischaemic aetiology and hypertensive aetiology were comparable between the Echo and No-Echo groups (p = NS). The cause of HF remained unidentified in 19.2% of patients in the No-Echo group compared to 2.5% in the Echo group (p < 0.001).
At discharge, patients in the No-Echo group received significantly lower prescription rates of ACE inhibitors, betablockers, aldosterone receptor antagonists, anticoagulants and amiodarone (Table 2) .
Clinical outcome
In the prematch population (n = 799), patients in the Echo group had a lower crude three-year overall mortality compared to those in the No-Echo group (HR 0.46, 95% CI 0.37-0.58, p < 0.001). On multivariable analysis, after adjustment for covariates, use of echocardiography was still associated with a lower risk of overall death (HR 0.61, 95% CI 0.48-0.78, p < 0.001) ( Table 3 and Fig. 1 ). The adjusted risk of three-year cardiovascular mortality was significantly lower in patients in the Echo-group compared with the NoEcho group (HR 0.52, 95% CI 0.39-0.70, p < 0.001) ( Table 3) . Similar results were obtained in patients surviving the index hospitalization ( Table 3) .
The one-, two-and three-year survival rates were dramatically lower in the No-Echo group compared to the expected survival of the age-and sex-matched general population (Fig. 2A) ; this difference was less impressive in the Echo group. The one-, two-and three-year relative survival rates (i.e. ratio of observed to expected survival) of the Echo group were higher than those in the No-Echo group (Fig. 2B) .
Associations between performance of echocardiography and overall mortality in subgroups of patients with HF are presented in Fig. 3 . The beneficial effect of performance of echocardiography was consistent across subgroups with the exception of the group of HF patients without renal insufficiency (p for interaction 0.04). There was no interaction of Figure 1 . Adjusted three-year overall mortality curves for patients with heart failure in the Echo and No-Echo groups. * Adjusted for age, sex, history of hypertension, ischaemic aetiology, diabetes mellitus, chronic obstructive pulmonary disease, cancer, stroke, estimated glomerular filtration rate, natremia, cardiomegaly and hospitalization in cardiology departments. performance of echocardiography with age (p = 0.26) or sex (p = 0.14). In propensity-matched patients (n = 238), the performance of echocardiography during hospitalization was associated with a significant 42% reduction in the relative risk of three-year crude overall mortality (HR 0.58, 95% CI 0.41-0.81, p = 0.001). After adjustment for covariates of prognostic importance and for propensity scores, the association remained significant (HR 0.55, 95% CI 0.39-0.79, p = 0.001). The risk of three-year cardiovascular mortality in matched patients was significantly lower for the Echo group (HR 0.59, 95% CI 0.37-0.95, p = 0.03). 
Discussion
This study shows that approximately 20% of patients hospitalized for a first episode of HF did not have an echocardiography during hospitalization. Patients in whom echocardiography was not performed received lower discharge prescription rates of ACE inhibitors, aldosterone receptor antagonists, beta-blockers, anticoagulants and amiodarone. Using propensity scores and multivariable analysis to reduce the significant imbalance in baseline characteristics between the Echo and No-Echo groups, we demonstrate that echocardiography was associated with a better clinical outcome. Thus, the three-year relative risk of overall and cardiovascular mortality of the NoEcho group was significantly higher than that of the Echo group. Moreover, a dramatic excess mortality compared to the expected survival of the age-and sex-matched general population was observed in patients in the No-Echo group.
Echocardiography is the investigation of choice to assess cardiac dysfunction [1, 2] . It is a cost-effective procedure that provides major prognostic data in patients with HF, including ejection fraction, left ventricular size, filling pressures, pulmonary pressures and, more recently, longitudinal contraction [9] . Recent data document the role of echocardiography in predicting age-related cardiovascular events in the general population, with a major impact on primary prevention strategies [10] . The technique is increasingly used to identify patients with structural heart disease, who are at risk of developing symptomatic HF [11] , and to assess response to therapy.
In recent cohort studies conducted in patients with HF, echocardiography was performed in 42 to 85% of cases [12] [13] [14] [15] . In our study, echocardiography was performed during the index hospitalization in 81% of patients admitted for a first episode of HF.
Patients in the No-Echo group were older and more frequently women. Renal insufficiency was more frequent among patients in the No-Echo group, probably as a consequence of their advanced age. Absence of cardiomegaly on the chest X-ray was related to the decision not to perform echocardiography, reflecting the fact that some non-cardiologists may still consider HF with preserved ejection fraction in elderly patients a less severe condition than systolic HF. However, recent reports demonstrate that these two conditions have comparable long-term prognosis [12, 13] . Advanced age was an important parameter associated with the decision not to perform echocardiography in patients hospitalized in geriatric departments and therefore managed largely by non-cardiologists. Recent studies have suggested that patients with HF treated by cardiologists differ significantly from those managed by internists, general practitioners and other physicians [16] [17] [18] , and that care by a cardiologist is associated with a reduced hazard for death and hospital readmission for HF in both hospitalized patients and outpatients with newonset HF [16, 19] . In all healthcare institutions participating in the present study, patients were grouped according to service (cardiology, internal medicine or geriatrics). However, as echocardiography facilities were institution based, lower ordering rates of echocardiograms in certain services (e.g. geriatrics) suggest a less intensive diagnostic and therapeutic approach in patients managed by noncardiologists.
In our study, patients in the No-Echo group received less aggressive therapy for HF and lower discharge prescription rates of life-saving drugs. This may be in part a consequence of the advanced age, high prevalence of renal insufficiency, and inherent difficulties in managing HF in elderly patients. It has also been reported that betablockers and ACE inhibitors are more frequently prescribed in patients treated by cardiologists [16, 17, 19] . Patients in whom echocardiography was performed probably had a more accurate diagnosis and therefore a better guidelinebased therapy.
Very few data are available on the prognostic impact of echocardiography in patients with HF. In a communitybased retrospective study involving 216 patients reported by Senni et al., crude survival was not significantly different between patients investigated by echocardiography and those in whom this examination was not performed [4] . However, after adjustment for age, sex and NYHA class, patients that did not undergo echocardiography had a poorer outcome. In our study, both crude and adjusted overall survival rates were lower in patients in the No-Echo group. The significantly higher mortality of the No-Echo group compared with that of the general population supports these findings.
Subgroup analyses revealed a striking mortality benefit of echocardiography in various categories of patients with HF. Interestingly, the performance of echocardiography was not associated with improved outcome in HF patients without renal insufficiency. It is widely acknowledged that patients with renal disease are at high risk for developing cardiovascular diseases, including HF. Impaired renal function is associated with higher death rates and more frequent hospitalizations in patients with chronic HF [20] . Assessment of cardiac function with echocardiography appears to be associated with greater survival benefit in high-risk patients with new-onset HF.
After the propensity-matching procedure, the performance of echocardiography remained associated with a significant reduction in the relative risk of three-year overall mortality. This result is important and supports our assumption that the lack of recognition of underlying heart diseases in the No-Echo group was the main factor precluding these patients from receiving appropriate therapy. Matched patients had comparable baseline variables including comorbidities, suggesting that these conditions apparently did not influence the therapeutic decision. Improved management of this elderly HF population by widespread use of echocardiography may have a favorable impact on survival and on prescription of appropriate therapy before discharge. The initiation of HF therapy before discharge results in improved compliance and better long-term clinical outcomes [21] .
Our study was exclusively hospital based with the advantage of prospectively recruiting all potential individuals who met the inclusion criteria. The main limitation of our study is that the performance of echocardiography was nonrandomized. However, a randomized trial comparing Echo versus non-Echo strategies has never been performed and seems ethically unacceptable. We acknowledge that subgroup analyses may be influenced by the small size of the samples and insufficient power to test for interactions [22] . In our cohort, although not systematically performed during the first hours after the patient's admission to hospital, echocardiography was available for the clinical decisionmaking. However, our data cannot exclude the confounding of intentional selection bias based on the patient's clinical status beyond the documented variables. Moreover, failure to order echocardiography may represent a marker of a passive management strategy. In our series, echocardiograms were not recorded on videotape. We acknowledge that off-line analysis of echocardiograms recorded on paper may be incomplete and that some abnormalities can be missed.
Conclusions
Echocardiography it still underused in patients admitted for a first episode of HF, especially in elderly patients managed by non-cardiologists. The use of echocardiography is associated with better quality of care and outcomes for in-patients with HF. Systematic use of echocardiography in all patients hospitalized for HF could improve diagnosis and prescription rates of life-saving drugs and substantially reduce the risk of future hospitalizations and death.
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